AspirinPlatelet Aggregation InhibitorsTiclopidinePlatelet AggregationPlatelet Function TestsBlood PlateletsHemorrhageDrug Therapy, CombinationThrombosisAnticoagulantsPurinergic P2Y Receptor AntagonistsAnti-Inflammatory Agents, Non-SteroidalFibrinolytic AgentsPlatelet ActivationThromboxane B2Receptors, Purinergic P2Y12DipyridamoleThienopyridinesCoronary ThrombosisBleeding TimeWarfarinThiophenesTreatment OutcomeAcute Coronary SyndromePhenprocoumonStrokePlatelet Glycoprotein GPIIb-IIIa ComplexStentsCyclooxygenase InhibitorsAngioplasty, Balloon, CoronaryMyocardial InfarctionRisk FactorsSalicylatesTime FactorsDrug-Eluting StentsPostoperative HemorrhageDrug ResistanceProspective StudiesSulfinpyrazoneThromboxanesPlatelet CountSecondary PreventionThromboembolismTetrazolesAdenosine DiphosphateTablets, Enteric-CoatedDose-Response Relationship, DrugFollow-Up StudiesCoronary Artery DiseaseThromboxane A2RecurrenceGastrointestinal HemorrhageHeparinRandomized Controlled Trials as TopicRisk AssessmentDouble-Blind MethodCyclooxygenase 1Ischemic Attack, TransientCerebrovascular DisordersDrug InteractionsPerioperative CareAdministration, OralPurinergic P2 Receptor AntagonistsCardiovascular DiseasesPhosphodiesterase 3 InhibitorsCoronary DiseaseImmunoglobulin Fab FragmentsThrombocytopeniaThrombelastographyBrain IschemiaRetrospective StudiesDrug Administration SchedulePiperazinesPurpura, ThrombocytopenicSodium SalicylatePlatelet AdhesivenessCerebral HemorrhageGraft Occlusion, VascularEmbolismIntracranial HemorrhagesProstaglandin-Endoperoxide SynthasesCardiovascular AgentsPercutaneous Coronary InterventionIntracranial ThrombosisThrombolytic TherapyInternational Normalized RatioEpoprostenolCyclooxygenase 2 InhibitorsBlood CoagulationP-SelectinAsthma, Aspirin-InducedPlatelet Membrane GlycoproteinsPhenazopyridineIncidenceThromboxane-A SynthasePyridinesCoronary AngiographyProton Pump InhibitorsAtrial FibrillationAcenocoumarol